Late relapse of germ cell tumors

Hematol Oncol Clin North Am. 2011 Jun;25(3):615-26, x. doi: 10.1016/j.hoc.2011.03.006.

Abstract

This article highlights relevant aspects of the rare late relapses of malignant germ cell tumors (MGCTs), which by definition occur at least 2 years after successful treatment. In most reports, 1% to 6% of patients with MGCT experience a late relapse. Surgery is the most important part in the treatment of late relapses. Viable MGCT or teratoma with malignant transformation may require multimodal treatment with chemotherapy, radiotherapy, and/or surgery. Salvage chemotherapy should be based on a representative biopsy. Referring patients with late relapse to high-volume institutions ensures the best chances of cure and enables multimodal treatment.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Combined Modality Therapy
  • Humans
  • Male
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasms, Germ Cell and Embryonal / drug therapy
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / therapy*
  • Survival Analysis
  • Teratoma / therapy
  • Testicular Neoplasms / drug therapy
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / therapy*
  • Time Factors